Neoplasia 2024

3 papers
In 2024, research in Neoplasia focused on clinical imaging, molecular mechanisms of drug resistance, and global epidemiological trends. One area of investigation involved the use of single-source dual-energy CT to assess the tumor microenvironment in non-small cell lung cancer, specifically comparing RECIST 1.1 criteria with pathological remission during neoadjuvant immunotherapy. This work highlights ongoing efforts to refine diagnostic accuracy in clinical settings. Molecular research during this period examined the PIK3R1 fusion as a driver of chemoresistance in ovarian cancer, identifying its role in activating the ERK1/2 pathway. Furthermore, the journal published systematic analyses of the global burden of retinoblastoma, utilizing data from 204 countries to track incidence and mortality over three decades. Prolific authors contributing to these themes included Chao Sun, Huimao Zhang, and Alejandra Cervera. These studies reflect a multi-disciplinary approach to oncology, combining diagnostic technology, molecular biology, and public health data.

Top Research Directions

The 1 research directions with Neoplasia 2024 papers, ranked by paper count. Share is the fraction of the edition’s papers in the direction.

#DirectionPapersShare
1Molecular Mechanisms of Resistance to Platinum Chemotherapy133.3%

Download all directions as CSV

Institutions

Institutions credited by Neoplasia 2024 papers: a paper credits every institution named in its affiliations, once. 6 institutions share 1 credited papers.

#InstitutionPapersShare
101qjckx08 1100.0%
205dbzj528 1100.0%
3Ferrari (Italy) 1100.0%
4University of Helsinki 1100.0%
5University of Modena and Reggio Emilia 1100.0%
6University of Turku 1100.0%

Download all institutions as CSV

About this data

Papers. Neoplasia 2024 lists 3 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers.

Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 1 of 3 papers (33.3%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.

Data. Counts come from Lacuna’s data build of 2026-11-20 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “Neoplasia 2024”, https://lacuna.tiptreesystems.com/venue/neoplasia/2024.

Top Authors

AuthorPapers
ELISA FICARRA1

Papers

Title
Incidence, mortality, and global burden of retinoblastoma in 204 countries worldwide from 1990 to 2021: Data and systematic analysis from the Global Burden of Disease Study 2021
PIK3R1 fusion drives chemoresistance in ovarian cancer by activating ERK1/2 and inducing rod and ring-like structures
Tumor microenvironment(TME) and single-source dual-energy CT(ssDECT) on assessment of inconformity between RECIST1.1 and pathological remission in neoadjuvant immunotherapy of NSCLC